226,000 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Ninety One UK Ltd

Ninety One UK Ltd purchased a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 226,000 shares of the medical research company's stock, valued at approximately $31,959,000. Ninety One UK Ltd owned about 0.17% of Natera as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Huntleigh Advisors Inc. increased its stake in Natera by 9.7% in the first quarter. Huntleigh Advisors Inc. now owns 10,027 shares of the medical research company's stock valued at $1,418,000 after purchasing an additional 890 shares during the last quarter. Calamos Advisors LLC increased its stake in Natera by 29.0% in the first quarter. Calamos Advisors LLC now owns 29,637 shares of the medical research company's stock valued at $4,191,000 after purchasing an additional 6,667 shares during the last quarter. Private Trust Co. NA increased its stake in Natera by 780.1% in the first quarter. Private Trust Co. NA now owns 1,461 shares of the medical research company's stock valued at $207,000 after purchasing an additional 1,295 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd purchased a new position in Natera in the first quarter valued at approximately $1,851,000. Finally, Amalgamated Bank increased its stake in Natera by 9.8% in the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock valued at $1,173,000 after purchasing an additional 740 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $166.77, for a total value of $500,310.00. Following the completion of the sale, the insider owned 130,205 shares of the company's stock, valued at approximately $21,714,287.85. This trade represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 5,343 shares of the firm's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $166.53, for a total value of $889,769.79. Following the completion of the sale, the chief executive officer directly owned 173,728 shares of the company's stock, valued at approximately $28,930,923.84. This trade represents a 2.98% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,272 shares of company stock worth $8,345,368 in the last ninety days. 7.60% of the stock is owned by insiders.

Analyst Ratings Changes

NTRA has been the subject of several research analyst reports. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Royal Bank Of Canada initiated coverage on Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price objective for the company. Piper Sandler increased their price objective on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Thursday, May 15th. UBS Group increased their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Finally, Barclays increased their price objective on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $184.63.

Natera Price Performance

Shares of NASDAQ NTRA opened at $158.69 on Tuesday. The stock has a fifty day moving average price of $160.45 and a 200 day moving average price of $158.42. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00. The company has a market cap of $21.67 billion, a PE ratio of -107.95 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same quarter last year, the company earned ($0.56) earnings per share. Natera's quarterly revenue was up 36.5% compared to the same quarter last year. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.